Federal Register Notices
View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
| View | Date Published | Title | Comments Close On | Dates |
|---|---|---|---|---|
| View | National Cancer Institute: Development of Idiotype Tumor Vaccines for Treatment of B-Cell Lymphoma | Organizations must submit a proposal summary preferably one page or less, to NCI within 90 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions will have established sufficient mutual interest. | ||
| View | Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress and the Prophylactic and Therapeutic Treatment Radiation Damage to Normal Tissue | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 8, 2000, will be considered. | ||
| View | Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress and in the Prophylactic and Therapeutic Treatment of Aging, Obesity and Cancer | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 8, 2000, will be considered. | ||
| View | Prospective Grant of Exclusive License: Glycoprotein Hormone Superagonists | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before April 7, 2000, will be considered. | ||
| View | Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources: Final Notice | |||
| View | National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Further Development and Commercialization of Methods Designed To Screen and Use Modulators of Nitric Oxide Synthase 2 (NOS2) Activity for the Diagnosis and Treatment of Cancer | Interested parties should notify the Technology Development and Commercialization Branch of the NCI in writing of their interest in filing a formal proposal no later than ( February 11, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. | ||
| View | Secretary's Advisory Committee on Genetic Testing | |||
| View | National Cancer Institute; Antitumor and Antimicrobial Lead Discovery and Development From Natural Products | Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential, preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before January 31, 2000. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest. | ||
| View | Prospective Grant of Exclusive License: ``Immunoconjugates Having High Binding Affinity'' | Only written comments and/or applications for a license which are received by NIH on or before February 24, 2000 will be considered. | ||
| View | Prospective Grant of Exclusive License: ``Diagnostic and Therapeutic Methods of Detecting and Treating Cancers of Reproductive Tissues'' | Only written comments and/or applications for a license which are received by NIH on or before January 14, 2000. | ||
| View | National Cancer Institute; Drug Research and Development of a Novel Vacuolar-Type (H+)-ATPase-Inhibitory Compound Class | Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before December 10, 1999. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Publication of the OIG Compliance Program, Guidance for Hospices | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: A Basal Cell Carcinoma Tumor Suppressor Gene | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 12, 1999. | ||
| View | Prospective Grant of Exclusive License: Vaccine to Treat and Prevent Disease Caused by Human Papillomaviruses, Particularly Cervical Cancer | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 8, 1999 will be considered. | ||
| View | Prospective Grant of Exclusive License: Conjugate Vaccines to Prevent Disease Caused by Nontypeable Haemophilus influenzae and Moraxella catarrahalis, Particularly Otitis Media | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 28, 1999 will be considered. | ||
| View | Opportunity for Licensing: Vasostation, an Inhibitor of Endothelial Cell Growth and Angiogenesis | In view of the priority for developing new antitumor agents, all proposals for either exclusive or non-exclusive licensing must be received on or before September 17, 1999. | ||
| View | Prospective Grant of Exclusive License: Glycoprotein Hormone Superagonists | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 17, 1999 will be considered. | ||
| View | National Institute of Dental and Craniofacial Research: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Either Diagnostics or Therapeutics for Bone Metastasizing Cancers Including Breast and Prostate Cancer | Interested parties should submit a one page statement of | ||
| View | Prospective Grant of Co-Exclusive License: Prodrug Forms of the Anti-Cancer Agent 9-greek-b-D-Arabinofuranosyl-2-Fluoroadenine as Therapeutics for the Treatment of Cancers and Leukemia | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before August 31, 1999 will be considered. | ||
| View | National Institute of Allergy and Infectious Diseases: Licensing Opportunity and/or Cooperative Research and Development Agreement (``CRADA'') Opportunity; Drug and Method for the Therapeutic Treatment of Respiratory Syncytial Virus and Parainfluenza Virus in Children | Respondents interested in licensing the invention will be required to submit an ``Application for License to Public Health Service Inventions'' on or before September 20, 1999, for priority consideration. | ||
| View | National Cancer Institute; Development of Anti-CD30 Monoclonal Antibody; for the Development of HeFi-1, Cooperative Research and Development Agreement | Inquiries regarding CRADA proposals and scientific matters may be forwrded at any time. Confidential CRADA proposals, preferably two pages or less, must be submitted to the NCI within 30 days from date of this publication. Guidelines for preparing a full CRADA proposal will be communicated shortly thereafter to the respondent who has been selected. | ||
| View | Annual Comprehensive List of Guidance Documents at the Food and Drug Administration | General comments on this list and on agency guidance documents are welcome at any time. | ||
| View | Government-Owned Inventions; Availability for Licensing: Cyanovirin-based Topical Microbicides for Prevention of Sexual Transmission of HIV |